Kalytera Therapeutics Appoints Pini Ben-Elazar to Board of Directors
March 17 2017 - 8:30AM
Kalytera Therapeutics, Inc. (TSXV:KALY) today announced that Mr.
Pini Ben-Elazar has been appointed to Kalytera’s Board of
Directors.
In connection with Kalytera’s recent acquisition of Talent
Biotechs, Ltd., the selling shareholders of Talent had the right to
nominate a person to join Kalytera’s Board of Directors. The
selling shareholders nominated Mr. Ben-Elazar.
Mr. Ben-Elazar is the Chief Executive Officer of Mor Research
Applications (“Mor”), a wholly-owned subsidiary of Clalit Health
Services (“Clalit”), the largest HMO in Israel. Mor serves as the
technology transfer arm for all inventions created by Clalit
professional staff and provides tools to develop ideas into
applicative research. Mor’s commercialization portfolio includes a
number of successful startups in the medical, pharmaceutical, and
biotechnology fields, and 60+ projects in various stages of
development.
About Kalytera TherapeuticsKalytera (TSXV:KALY)
is a clinical-stage pharmaceutical company pioneering the
development of a next generation of cannabinoid therapeutics.
Through its proven leadership, drug development expertise, and
intellectual property portfolio, Kalytera seeks to establish a
leading position in the development of novel cannabinoid medicines
for a range of important unmet medical needs, with an initial focus
on Graft versus Host Disease (“GvHD”). Kalytera is also developing
a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is
a remarkable compound that has shown activity against a number of
pharmacological targets. However, there are limitations associated
with natural CBD, including its poor oral bioavailability. Kalytera
is developing innovative CBD formulations and prodrugs in an effort
to overcome these limitations, and to target specific disease sites
within the body. Kalytera intends to file composition of matter and
method of use patents covering its novel inventions, with the goal
of limiting future competition.
- Website Home: https://kalytera.co/
- News and Insights: https://kalytera.co/news/
- Investors: https://kalytera.co/investors/
Forward-Looking Statement DisclosureThis news
release may contain “forward-looking information” within the
meaning of applicable securities laws. Although Kalytera believes
in light of the experience of its officers and directors, current
conditions and expected future developments and other factors that
have been considered appropriate, that the expectations reflected
in this forward-looking information are reasonable, undue reliance
should not be placed on them because Kalytera can give no assurance
that they will prove to be correct. Readers are cautioned to not
place undue reliance on forward-looking information. Actual results
and developments may differ materially from those contemplated by
these statements. The statements in this press release are made as
of the date of this release. Kalytera undertakes no obligation to
comment on analyses, expectations or statements made by
third-parties in respect of Kalytera, its securities, or its
respective financial or operating results (as applicable). Kalytera
disclaims any intent or obligation to update publicly any
forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
Company Contact
Robert Farrell
President, COO and CFO
Phone: (888) 861-2008
Email: ir@kalytera.co
Kalytera Therapeutics (TSXV:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kalytera Therapeutics (TSXV:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024